← ANALYST RATINGS · TIPRANKS
Lexicon Pharmaceuticals (LXRX): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $5.78, the highest $8.00, the lowest $3.10. The average is +279.9% from the last price of $1.52.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.00 → $1.50−25.0% | Hold | −1.3% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 → $1.50−25.0% | Hold | −1.3% | Reiterated | 07.10.26on TipRanks Oct 6 23:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.00 | Hold | +31.6% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.00 | Hold | +31.6% | Downgrade | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.00 | Hold | +31.6% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $1.50 → $2.00+33.3% | Hold | +31.6% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.00 | Hold | +31.6% | Downgrade | 01.10.26on TipRanks Sep 30 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 | Hold | +31.6% | Reiterated | 01.10.26on TipRanks Sep 30 23:05 | — | |
| Steven Seedhouse★★★★★★★★★★#1374 · hits 43% · avg +10.3% | Cantor Fitzgerald | $8.00 | Buy | +426.3% | Initiated | 28.09.26on TipRanks 06:35 | +6.6%next day −0.9% · 5 days −9.6% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $3.10 | Buy | +103.9% | Reiterated | 10.09.26on TipRanks Sep 11 04:15 | −5.4%next day −1.8% · 5 days +0.1% | ↗ |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $6.00 | Buy | +294.7% | Reiterated | 24.08.26on TipRanks 10:50 | +1.2%next day +0.5% · 5 days −3.5% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $6.00 | Buy | +294.7% | Reiterated | 07.08.26on TipRanks 11:27 | +4.1%next day −2.8% · 5 days −6.5% | ↗ |
| Unknown Analyst | Leerink Partners | $1.00 | Hold | −34.2% | Reiterated | 06.03.26on TipRanks 09:40 | +5.6%next day −2.6% · 5 days +0.3% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Lexicon Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $5.78 at a price of $1.88 (+208.0%); now: $5.78 at $1.52 (+279.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 2 | 3 | 5 | 7 | 5 |
| Buy | 2 | 1 | 1 | 0 | 0 | 0 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.06 (from $-0.07 to $-0.04). Last quarter: $-0.07.
Sales
Next quarter’s sales estimate — $4M (from $0M to $11M). Last quarter: $1M.
Best top-analyst consensus in the sector · Healthcare
About Lexicon Pharmaceuticals
- CEO: Michael S. Exton
- Employees: 81
- 2445 Technology Forest Boulevard, The Woodlands, TX, 77381, US
- www.lexpharma.com
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
Data from the stock’s TipRanks forecast page, read 27 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗